Baird Medical completed its first bone‑tumor ablation in Egypt at Ain Shams Specialized Hospital, treating a 30‑year‑old male with a 1 × 1.5 cm bone lesion and achieving full ablation and pain relief.
The procedure demonstrates Baird Medical’s ability to deploy its microwave ablation technology outside China and is supported by a Certificate to Foreign Government from the FDA, which facilitates market entry in Egypt and other countries that recognize FDA standards.
The launch marks the company’s first minimally invasive treatment in Egypt and provides a foothold in the Middle Eastern and North African region, where the oncology therapeutics market is projected to reach $1.1 billion by 2030.
Baird Medical reported six‑month revenue of $13.1 million, up 13.8% from the same period in 2023, and gross profit of $11.5 million, up 20.9%. The company’s Nasdaq listing on October 2, 2024, and its ongoing CE‑Mark applications support its global expansion strategy.
Baird Medical competes with Mermaid Medical and AngioDynamics in the MWA market, which is projected to grow at a CAGR of 12.54% from 2025 to 2034. The successful Egyptian procedure showcases the versatility of Baird Medical’s MWA system for musculoskeletal applications.
The company plans to pursue additional regulatory approvals in the MENA region and expand its MWA portfolio into other oncologic indications, leveraging the demonstrated success in Egypt to attract new customers and partners.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.